Search Results

You are looking at 1 - 10 of 686 items for :

  • "metastases" x
Clear All
Full access

Priscilla K. Brastianos, William T. Curry and Kevin S. Oh

Background An estimated 8% to 10% of patients with cancer will develop symptomatic brain metastases. 1 , 2 The geographic distribution of metastases reflects the volume of brain parenchyma and vascular flow: approximately 80% within cerebral

Full access

Fabian M. Johnston, Michael N. Mavros, Joseph M. Herman and Timothy M. Pawlik

Traditionally, local therapy for hepatic metastases has been largely reserved for patients with colorectal liver metastases (CRLM) or, less often, neuroendocrine liver metastases (NELM). Colorectal cancer is one of the most common types of cancer

Full access

Kazuki Sudo, Xuemei Wang, Lianchun Xiao, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, David C. Rice, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Adarsh Hiremath, Nikolaos Charalampakis, Ritsuko Komaki, Mariela A. Blum, Stephen G. Swisher, Dipen M. Maru, Heath D. Skinner, Jeana L. Garris, Jane E. Rogers, Wayne L. Hofstetter and Jaffer A. Ajani

Background Among patients with localized esophageal cancer (LEC), 35% or more develop distant metastases (DM) as first relapse, most in the first 24 months after local therapy. 1 Worldwide, yearly new cases of esophageal cancer are estimated

Full access

Nancy Kemeny

arterial infusion (HAI) for the treatment of liver only metastases. I believe 3 circumstances exist in which HAI therapy may be considered. The first is after liver resection. Four randomized controlled trials address the use of HAI therapy after hepatic

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias and Giovanni Casazza

adjuvant setting of breast cancer might have any effect on the natural course of the disease. Most specifically, they investigated for any beneficial effects on overall survival, prevention of disease recurrences, and occurrence of bone metastases

Full access

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia and Jean-Nicolas Vauthey

Background Approximately 15% of patients with colorectal cancer (CRC) have synchronous colorectal liver metastases (CLM; detected at initial diagnosis or during treatment after initial diagnosis), and approximately 30% of patients with CRC have

Full access

Sajeel Chowdhary and Marc Chamberlain

The authors have no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1 Kaplan JG DeSouza TG Farkash A . Leptomeningeal metastases

Full access

Jeffrey F. Moley

clinical cervical lymph node involvement is as high as 75%, and additional occult metastases may be present. 10 , 11 Clinical complaints, including respiratory difficulty, hoarseness, and dysphagia, are present in approximately 15% of patients with

Full access

Richard L. Theriault

OS Munro AJ Tannock IF . Bone metastases: pathophysiology and management policy . J Clin Oncol 1991 ; 9 : 509 – 524 . 7 Coleman RE Smith P Rubens RD . Clinical course and prognostic factors following bone recurrence from breast cancer

Full access

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky and Yoshiya Yamada

2003 to 2009. 1 At presentation, 25% of patients will demonstrate metastases, and 25% who undergo nephrectomy for localized disease will ultimately develop recurrent or metastatic tumor. 1 Targeted therapies directed against vascular endothelial